摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,6-二氯-4-甲基吡啶 | 39621-00-6

中文名称
2,6-二氯-4-甲基吡啶
中文别名
——
英文名称
2,6-dichloro-4-picoline
英文别名
2,6-dichloro-4-methylpyridine;2,6-Dichlor-4-methyl-pyridin
2,6-二氯-4-甲基吡啶化学式
CAS
39621-00-6
化学式
C6H5Cl2N
mdl
MFCD09264302
分子量
162.018
InChiKey
GTHRJKYVJZJPCF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    65.0-66.0 °C(Solv: ligroine (8032-32-4))
  • 沸点:
    122-123 °C(Press: 22-23 Torr)
  • 密度:
    1.319±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    12.9
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2933399090
  • 危险性防范说明:
    P280,P305+P351+P338,P310
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    -20℃

SDS

SDS:5dc308590a73f8dedd751da8b420d453
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2,6-Dichloro-4-methylpyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H318: Causes serious eye damage
H315: Causes skin irritation
H302: Harmful if swallowed
H335: May cause respiratory irritation
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

Section 3. Composition/information on ingredients.
Ingredient name: 2,6-Dichloro-4-methylpyridine
CAS number: 39621-00-6

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H5Cl2N
Molecular weight: 162

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2,6-二氯-4-甲基吡啶 作用下, 以 为溶剂, 反应 10.0h, 以51%的产率得到2-氨基-6-氯-4-甲基吡啶
    参考文献:
    名称:
    [EN] TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS
    [FR] COMPOSÉS DE TRIAZOLOPYRIDINE ET LEUR UTILISATION COMME INHIBITEURS DE ASK
    摘要:
    本发明涉及三唑吡啶化合物,其化学式为(I),其用作药物,用于治疗自身免疫性疾病、炎症性疾病、心血管疾病和/或神经退行性疾病,以及其制备方法。
    公开号:
    WO2009027283A1
  • 作为产物:
    描述:
    2-氯-4-甲基吡啶间氯过氧苯甲酸三氯氧磷 作用下, 以 二氯甲烷甲苯 为溶剂, 反应 28.0h, 生成 2,6-二氯-4-甲基吡啶
    参考文献:
    名称:
    [EN] ANTIVIRAL COMPOUNDS
    [FR] COMPOSÉS ANTIVIRAUX
    摘要:
    本文披露了新的抗病毒化合物,以及包括一种或多种抗病毒化合物的药物组合物,以及合成这些化合物的方法。本文还披露了使用一种或多种小分子化合物改善和/或治疗副粘病毒病毒感染的方法。副粘病毒感染的例子包括由人类呼吸道合胞病毒(RSV)引起的感染。
    公开号:
    WO2015026792A1
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
    申请人:GLAXOSMITHKLINE LLC
    公开号:US20150152108A1
    公开(公告)日:2015-06-04
    The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    本发明涉及新型取代桥式脲化合物,相应的相关类似物,药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命,并治疗和/或预防各种疾病和疾病,包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病,以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
  • [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
    申请人:GLAXOSMITHKLINE IP NO 2 LTD
    公开号:WO2016079709A1
    公开(公告)日:2016-05-26
    The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
    本发明涉及一种新型的取代桥式脲类似物化合物,其化学式为(I)或其药学上可接受的盐,相应的药物组合物,制备这种化合物的方法以及单独使用或与其他治疗剂联合使用的这些化合物作为Sirtuin调节剂,可用于增加细胞寿命,并用于治疗和/或预防各种疾病和紊乱,包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱,以及那些会受益于增加线粒体活性的疾病或紊乱。
  • 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS
    申请人:Payne Lloyd James
    公开号:US20110009390A1
    公开(公告)日:2011-01-13
    The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.
    该发明提供了式(I)的化合物,以及其在药学和农业上可接受的盐:其中:R1、R2、R3、R4、R5、R6、R7、R8、A1、L1和n如本文所定义。这些化合物及其药学上可接受的盐在制造用于预防或治疗真菌病的药物方面是有用的。式(I)的化合物及其在农业上可接受的盐也可用作农业杀菌剂。
  • [EN] HEPATITIS B VIRAL ASSEMBLY EFFECTORS<br/>[FR] EFFECTEURS D'ASSEMBLAGE DE VIRUS DE L'HÉPATITE B
    申请人:UNIV INDIANA RES & TECH CORP
    公开号:WO2016168619A1
    公开(公告)日:2016-10-20
    Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.
    揭示了一种对乙型肝炎病毒(HBV)感染具有治疗效果的新型组装效应子化合物。本文描述的组装效应子分子可以导致病毒组装缺陷,也可能影响与慢性HBV感染相关的其他病毒活动。还公开了一种合成所述化合物的方法,通过给予所述化合物治疗HBV的方法,以及利用这些化合物制造针对HBV的药物的用途。
  • THERAPEUTIC COMPOUNDS
    申请人:CELGENE QUANTICEL RESEARCH, INC.
    公开号:US20170298040A1
    公开(公告)日:2017-10-19
    The present disclosure relates to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of diseases mediated by aberrant cell signalling, such as inflammatory disorders, cancer and neoplastic disease.
    本公开涉及替代杂环衍生治疗化合物,包括所述化合物的组合物,以及通过抑制溴结构域介导的乙酰赖氨酸区域对蛋白质(如组蛋白)的识别来进行表观遗传调控的所述化合物和组合物的用途。所述组合物和方法对于治疗由异常细胞信号传导介导的疾病,如炎症性疾病、癌症和肿瘤性疾病,是有用的。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-